As a long term shareholder I am 95% certain the journal is coming.
Personally I think it’s running 50% bait and switch to a lower tier journal (this is supported by NWBO’s actions last time we waited forever on a much ballyhooed journal article.
Again in my opinion it’s about a 45% chance of a journal article in a major journal (though with a real risk of a lower impact that hopes for just as TLD had a lower impact than hoped for.
That leaves 5% of no article at all because this is NWBO, just like there was no Phase 2 for EAMS, no Phase 2 DCVax Direct and no Phase 3 DCVax Prostate.
The problem is, as with the TLD release slated for September 2020 and no article to go with the actual TLD release in May 2022x, NWBO has a habit of taking even the smallest window for screwing up and going with that even though the odds should have heavily favored effective execution and a huge and permanent SP increase with a new and high floor.
News 
Market Data 
Discover 
